Результаты поиска

Amino acids metabolism: a potential target for cancer treatment.

Metabolic reprogramming of amino acids has been recognized as a significant characteristic in various types of cancers. Numerous studies have indicated that the metabolic reprogramming of amino acids in tumors significantly supports certain malignant behaviors, including tumor proliferation, survival, invasion, and even immune escape. Amino acids can provide biomolecules such as nucleotides and glutathione (GSH) for tumors, and the bioavailability of amino acids influences tumor progression. Meanwhile, as essential metabolites, amino acids are closely associated with immune cell activation and

RNA modifications in cancer.

RNA modifications are emerging as critical cancer regulators that influence tumorigenesis and progression. Key modifications, such as N6-methyladenosine (m6A) and 5-methylcytosine (m5C), are implicated in various cellular processes. These modifications are regulated by proteins that write, erase, and read RNA and modulate RNA stability, splicing, translation, and degradation. Recent studies have highlighted their roles in metabolic reprogramming, signaling pathways, and cell cycle control, which are essential for tumor proliferation and survival. Despite these scientific advances, the precise

Immunosenescence, Physical Exercise, and their Implications in Tumor Immunity and Immunotherapy.

Aging is associated with a decline in immune function, termed immunosenescence, which compromises host defences and increases susceptibility to infections and cancer. Physical exercise is widely recognized for its myriad health benefits, including the potential to modulate the immune system. This review explores the bidirectional relationship between immunosenescence and physical exercise, focusing on their interplay in shaping antitumor immunity. We summarize the impact of aging on innate and adaptive immune cells, highlighting alterations that contribute to immunosenescence and cancer develo

Совпадение в полном тексте источника
… Qi Wu, and a National Natural Science Foundation of China (NSFC) grant (Grant NO: 82303284) to Dr. Bei Li. Author contributions QW, SS and WL performed and conceived the review. XY and WP wrote the manuscript. XY, WP and BL drew all the figures. …

Nanomaterials in gene therapy and genome editing: challenges and emerging directions.

Nanomaterials are redefining the landscape of gene and genome editing, yet their translation to clinical reality remains constrained by multiple unresolved challenges. While they provide structural and functional advantages for delivering nucleic acids and CRISPR/Cas systems across biological barriers, their behavior within living systems is often unpredictable, leading to issues such as off-target editing, immune activation, and inconsistent biodistribution. The design of nanocarriers, whether lipid-based, polymeric, inorganic, must therefore balance efficiency with safety, integrating physic

Screening the Active Phytochemicals From Eclipta prostrata and Unraveling Their Molecular Insight Into Human Malignancies.

Current drugs against multiple human malignancies are limited, and developing new treatment strategies is improbable within a short time. So, considering the current situation, phytochemicals could be a viable option for developing chemotherapeutic agents for managing numerous types of malignancies. Therefore, we aimed to locate all phytochemicals of Eclipta prostrata and unravel their chemotherapeutic mechanisms and strategies individually. We defined 25 active compounds based on their anticancer activities after filtering through IMPPAT and literature search, and these compounds have chemoth

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.

Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, Bruton tyrosine kinase, FLT3, BCL-2, IDH1, IDH2, are biomarker-driven chemotherapy-free agents approved for several major hematological malignancies. LOXO-305, asciminib, "off-the-shelf" universal CAR-T cells and BCMA-directed immunotherapeutics as well as data from clinical trials on many novel agents and regimens were updated at the 2020 American Society of Hematology (ASH) Annual Meeti

Current landscape of innovative drug development and regulatory support in China.

The global pharmaceutical landscape remains dynamic and competitive, shaped by advancements in first-in-class therapies and breakthrough technologies. The United States has maintained its leadership in first-in-class therapies and breakthrough technologies, driven by advanced regulatory pathways, significant multinational corporation investments, a robust Research and Development (R&D) workforce, and continuous technological innovation. Additionally, global impact of the Food and Drug Administration (FDA) is further amplified through collaborations like Project Orbis, which facilitates simulta

Совпадение в полном тексте источника
… Yiqi Tongqiao Pills 09/14/2021 Tianjin Dongfang Huakang Seasonal allergic rhinitis (lung and spleen qi deficiency syndrome) TCM compound preparation based on clinical experience. … Yiqi Tongqiao Pills | 09/14/2021 | Tianjin Dongfang Huakang | Seasonal allergic rhinitis (lung and spleen qi deficiency syndrome) | TCM compound preparation based on clinical experience. CGT products have emerged as innovative therapeutic options for an array of refractory and rare diseases. …

Natural bioactive molecules and chemotherapeutics synergism for enhanced cancer therapy.

BACKGROUND: Chemotherapy remains a foundation of cancer care but is limited by multidrug resistance, systemic toxicities, and suboptimal selectivity, prompting interest in adjunctive strategies that improve efficacy and tolerability without adding significant burden to patients or healthcare systems. AIMS/OBJECTIVES: This review highlights evidence on natural bioactive compounds, including polyphenols, alkaloids, terpenoids, and fungal metabolites, as adjuvants to standard chemotherapeutics, with objectives to: first, delineate mechanisms by which these agents enhance cytotoxic efficacy and o

Spiegelmer Aptamers: Innovative Approach in Breast Cancer.

Breast cancer remains one of the leading causes of cancer-related mortality among women worldwide, emphasizing the urgent need for improved diagnostic and therapeutic strategies. Aptamers which are synthetic oligonucleotides that specifically bind to target molecules, offer high affinity, low immunogenicity, and superior tumor penetration compared to antibodies. However, their clinical translation has been limited by instability in biological systems. Spiegelmers, a novel class of mirror-image aptamers composed of L-nucleotides, overcome this limitation through intrinsic nuclease resistance an

Совпадение в полном тексте источника
… Liu X, Fang Y, Li Y, Li Y, Qi L, Wang X. Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Oncology. 2022;12:894861. 76. Watkins EJ. …

Development Trends of Janus Kinase Inhibitors (JAKi) Over Three Decades: From Common to Rare Diseases.

Janus kinase inhibitors (JAKi) have undergone three decades of research and development, demonstrating substantial therapeutic efficacy and broad clinical applicability in autoimmune diseases, inflammatory disorders, hematopoietic malignancies, and a spectrum of rare diseases. However, their research and development are constrained by three key challenges: the difficulty in target selection and safety concerns arising from their effects on cellular signaling pathways, as well as the challenges in formulating optimal dosing regimens due to interindividual variability in pharmacokinetics. In thi

Совпадение в полном тексте источника
… Lv Y , Qi J , Babon JJ , et al. The JAK-STAT pathway: from structural biology to cytokine engineering . Signal Transduct Target Ther . 2024 ; 9 ( 1 ): 221 . doi: 10.1038/s41392-024-01934-w 39169031 PMC11339341 2. Mohamed MF , Bhatnagar S , Parmentier JM , et al. …

Advances in antisense oligonucleotide treatment for cancer.

RNA therapeutics, including antisense oligonucleotides (ASOs), have emerged as a promising class of drugs, with several already approved for clinical use. To date, most approved ASO-based RNA therapies target non-malignant disorders such as neurodegenerative diseases, and only a single therapy in this class has been approved for cancer. Notably, nearly half of existing RNA therapeutics act by modulating RNA splicing. Given the growing evidence implicating aberrant RNA splicing in cancer pathogenesis, the development of ASO-based therapeutics for oncologic indications is expected to accelerate.

Совпадение в полном тексте источника
… Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol 2013;26:155–65. 10.1038/modpathol.2012.160. 161. Amodio N, Stamato MA, Juli G, et al. …

A new era of natural killer cell immunotherapy in tumor treatment: latest advances and cutting-edge perspectives from basic research to clinical practice.

As early as 1863, Virchow observed that cancer often arises at sites of chronic inflammation. Modern epidemiological and clinical studies have confirmed the link between inflammation and cancer. Natural Killer (NK) cells actively participate in and regulate inflammatory processes; however, they are not strictly classified as classic 'inflammatory cells' in cellular taxonomy. NK cells rapidly identify and eliminate malignantly transformed cells in a non-major histocompatibility complex (MHC)-restricted manner, a characteristic that distinguishes them from other immune cells. Furthermore, their

Совпадение в полном тексте источника
… PMID: 31623687 PMC6798508 60 Tang F Li J Qi L Liu D Bo Y Qin S . A pan-cancer single-cell panorama of human natural killer cells . Cell . ( 2023 ) 186 : 4235 – 4251.e20 . doi: 10.1016/j.cell.2023.07.034 . PMID: 37607536 61 Baginska J Viry E Paggetti J Medves S Berchem G Moussay E . …

Prognostic value of the Controlling Nutritional Status (CONUT) score in cancer: an umbrella review of systematic reviews and meta-analyses.

BACKGROUND: The Controlling Nutritional Status (CONUT) score, combining serum albumin, total cholesterol, and lymphocyte count, has shown promise as a prognostic biomarker in various cancers, but a comprehensive assessment across different cancer types remains lacking. METHODS: We systematically searched PubMed, Embase, Web of Science, and the Cochrane Database of Systematic Reviews from inception to October 2025 and identified 40 meta-analyses reporting 86 outcomes [7 non-statistically significant (P ≥ 0.05) and 79 statistically significant (P < 0.05)] related to the CONUT score and cancer p

Совпадение в полном тексте источника
… Li Z Lin Y Shi Y Yang T An L Qi Y . Association between malnutrition diagnosed by different screening and assessment tools and clinical outcomes: an umbrella review . Front Nutr. ( 2025 ) 12 : 1676201 . doi: 10.3389/fnut.2025.1676201 41141259 PMC12545068 66. Yang J Wang C Xue J Ma X Hou Y Yuan H . …

BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.

Myasthenia gravis (MG) is an autoimmune disorder characterized by B cell dysfunction. Here, we designed B cell maturation antigen (BCMA)/CD19 chimeric antigen receptor T cell (CAR T cell) therapy for six refractory MGs, demonstrating favorable safety with grade 1 cytokine release syndrome observed. CAR T cell expansion induced profound B cell depletion, a sustained reduction in acetylcholine receptor (AChR) antibody titers, and symptom improvement. Five patients achieved drug-free remission with minimal manifestations by month 6, persisting through the 12-month follow-up despite B cell reconst

Совпадение в полном тексте источника
… Qi , D. Li , F. Zhu , Z. Li , J. Qiao , Q. Wu , L. Zeng , X. Fei , W. Gu , Y. Miao , K. Xu , J. Zheng , J. Cao , Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: A phase I/II trial . Nat. …

Osteoprotegerin and receptor activator of NF-kappaB ligand as biomarkers for bone resorption-related disorders.

Osteoclastic bone diseases represent a significant health burden, especially in an aging population, due to imbalances in bone homeostasis that result in postmenopausal osteoporosis, inflammatory arthritis, malignancy-induced bone disease and secondary metabolic conditions, which result in fragility fractures, disability and death. Although advances in imaging and pharmacology have enhanced management, existing diagnostic strategies have poor sensitivity in detecting early-stage pathological changes or fracture risk. The NF-kappaB/receptor activator of NF-kappaB ligand (RANKL)/osteoprotegerin

Совпадение в полном тексте источника
… Kitaura H, Marahleh A, Ohori F, Noguchi T, Shen WR, Qi J, Nara Y, Pramusita A, Kinjo R, Mizoguchi I. Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption. Int J Mol Sci. 2020;21:5169. doi: 10.3390/ijms21145169. 39. …

Токсичность CAR-T, биконкретных антител и антителных соединений в Множественной миеломе: практический подход к уменьшению рисков и управлению ими.

Антигены созревания B-клеток (BCMA), группа рецепторов с белковым сцеплением C 5 Член группы D (GPRC5D) под руководством иммунотерапии, продуктов химерика антигенного рецептора Т-клестера (CAR-T), лиц, занимающихся деятельностью в двух конкретных Т-клетках (BsAbs), и лиц, занимающихся антителными препаратами (ADC), изменил управление MM. В настоящее время их внедрение выходит за рамки высших центров после внесения изменений в УЛХ для обеспечения безопасности CAR-T и быстрого внедрения недр, пригодных для общинной доставки. Поэтому врачи, находящиеся вне специализированных центров, должны быть

Совпадение в полном тексте источника
… Qi K. Verona R. Doyle M. Incidence, Timing, and Management of Infections in Patients Receiving Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma in the MajesTEC-1 Study Cancer 2024 130 886 900 10.1002/cncr.35107 37960969 …

Цель METTL3/m6A/SOCS3 перепрограммирует макрофажную поляризацию, связанную с опухолью, с тем чтобы повысить эффективность анти-PD-1-терапии в множестве миеломы.

ИССЛЕДОВАНИЯ: В ходе этого исследования были изучены функции иммуномодулятора подавителя цитокина, сигнализирующего 3 (SOCS3) в макрофаге поляризации и активации цитотоксичных Т-клеток в микроопухоли (TME) множественной миэломы (MM). МЕТОДЫ: Выражение SOCS3 оценивалось в клинических образцах MM и здоровом контроле. Для разъяснения воздействия SOCS3 на злокачественное развитие клеток MM и поляризацию макрофага были разработаны анализы эффективности и потери функций, а также система кокультуры MM-камер. В рамках механистических исследований основное внимание было уделено модуляции SOCS3 при помо

Совпадение в полном тексте источника
… Qi Y, Li R, Han M (2024) Tumor-associated macrophages induce epithelial-mesenchymal transition and promote lung metastasis in breast cancer by activating the IL-6/STAT3/TGM2 axis. Int Immunopharmacol 143:113387. 10.1016/j.intimp.2024.113387 40. …

Liposomal Nanoparticle Delivery of Ginkgo Flavone Glycosides Enhances SIRT1 Activation and Improves Diabetic Cardiomyopathy.

PurposeThis study aims to explore the therapeutic mechanisms of Ginkgo Flavone Glycosides (GFGs) delivered via liposomal nanoparticles in treating Diabetic Cardiomyopathy (DCM) by upregulating Sirtuin 1 (SIRT1) to restore energy metabolism and autophagy homeostasis.MethodsA DCM mouse model was employed, with groups treated with different doses of GFGs. Various evaluations, including body weight, blood glucose levels, and cardiac function, were performed. Network pharmacology, transcriptomic analysis, and molecular docking studies were conducted to elucidate the key role of SIRT1 in inhibiting

Совпадение в полном тексте источника
… Zheng Y, Lang Y, Qi B, Li T. TSPAN4 and migrasomes in atherosclerosis regression correlated to myocardial infarction and pan-cancer progression. Cell Adh Migr . 2023;17(1):14–19. doi: 10.1080/19336918.2022.2155337 42. Dong G, Wang B, An Y, et al. …

Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence.

Antibody-drug conjugates (ADCs) are rapidly developing targeted cancer therapeutic agents that combine specific monoclonal antibodies with cytotoxic agents. Currently, 17 ADCs are approved for the global market for treating hematological and solid tumors with more than 100 ADCs are in phase III clinical trials. ADC-induced hepatotoxicity is a significant concern with unclear mechanisms, and the incidence of hepatic adverse events (AEs) varies across different ADCs. Most hepatic AEs are moderate; however, some ADCs can cause life threatening or fatal AEs. The management of hepatic AEs is limite

Совпадение в полном тексте источника
… Oncol. 25 (2), 455–461. 10.1093/annonc/mdt566 Li X., Zhou M., Qi J., Han Y. (2021). Efficacy and safety of inotuzumab ozogamicin (CMC-544) for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-hodgkin lymphoma: a systematic review and meta-analysis. Clin. …

Pathophysiological Roles of the CX3CL1-CX3CR1 Axis in Renal Disease, Cardiovascular Disease, and Cancer.

CX3CL1 and its unique receptor, CX3CR1, are leukocyte migration factors and are involved in the pathogenesis and progression of many inflammatory diseases and malignancies. The CX3CL1-CX3CR1 axis induces a variety of responses, including cell proliferation, migration, invasion, and apoptosis resistance. CX3CL1 is a transmembrane protein, and proteolysis generates a soluble form. The membrane and soluble forms of CX3CL1 exhibit different functions, but both bind to the chemokine receptor CX3CR1. The CX3CL1-CX3CR1 axis is a chemokine system that has attracted attention not only as a therapeutic

Совпадение в полном тексте источника
… Qi T. Li D. Chen Y. Ji X. Zhang Y. Chen W. Independent Roles of Monocyte Chemoattractant Protein-1, Regulated on Activation, Normal T-Cell Expressed and Secreted and Fractalkine in the Vulnerability of Coronary Atherosclerotic Plaques Circ. …